Success Metrics

Clinical Success Rate

91.7%

Based on 11 completed trials

Completion Rate

92%(11/12)

Active Trials

1(5%)

Results Posted

64%(7 trials)

Terminated

1(5%)

Phase Distribution

Ph phase_4

Ph phase_1

15%

Ph phase_3

10%

Ph phase_2

45%

Ph not_applicable

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution19 total trials

Phase 1Safety & dosage

3(15.8%)

Phase 2Efficacy & side effects

9(47.4%)

Phase 3Large-scale testing

2(10.5%)

Phase 4Post-market surveillance

1(5.3%)

N/ANon-phased studies

4(21.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(11)

Terminated(2)

Other(6)

Detailed Status

Completed11

unknown5

Terminated1

Recruiting1

Withdrawn1

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

91.7%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (15.8%)

Phase 29 (47.4%)

Phase 32 (10.5%)

Phase 41 (5.3%)

N/A4 (21.1%)

Trials by Status

completed1155%

terminated15%

unknown525%

recruiting15%

withdrawn15%

suspended15%

Recent Activity

1 active trials

Showing 5 of 20

suspendedphase_1

D-serine AudRem: R33 Phase

NCT05046353

recruitingphase_2

D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression

NCT07312110

completednot_applicable

Clinical Trials (20)

Showing 20 of 20 trials

NCT05046353Phase 1

D-serine AudRem: R33 Phase

Suspended

NCT07312110Phase 2

D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression

Recruiting

NCT04721249Not Applicable

D-serine Supplementation for Depression

Completed

NCT04140773Not Applicable

The Effect of D-serine as add-on Therapy in Recent-onset Psychosis

Terminated

NCT03711500Phase 1

D-serine Augmentation of Neuroplasticity

Completed

NCT02156908Phase 2

D-serine and Cognitive Remediation in Schizophrenia

Completed

NCT00322023Phase 2

Safety and Effectiveness of D-serine in Schizophrenia

Completed

NCT03778320Phase 1

A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers

Completed

NCT03702933

D-serine in Schizophrenia

Unknown

NCT01804920Not Applicable

D-Serine Treatment For Tardive Dyskinesia

Unknown

NCT01018056Phase 4

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

Completed

NCT00826202Phase 2

D-serine for the Schizophrenia Prodrome

Completed

NCT00237809Phase 3

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

Completed

NCT02051426Not Applicable

Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans

Completed

NCT01715051Phase 2

D-Serine for Cocaine Dependence Pilot

Withdrawn

NCT00816894Phase 2

D-serine Monotherapy for Schizophrenia

Completed

NCT01474395Phase 2

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Unknown

NCT00237848Phase 3

D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia

Completed

NCT01459029Phase 2

High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia

Unknown

NCT00138775Phase 2

Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

Unknown

All 20 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 20